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ABSTRACT
RNA interference (RNAi) has emerged recently as
an efficient mechanism for specific gene silencing.
Short double-stranded small interfering RNAs
(siRNAs) are now widely used for cellular or drug
target validation; however, their use for silencing
clinically relevant genes in a therapeutic setting
remains problematic because of their unfavourable
metabolic stability and pharmacokinetic properties.
To address some of these concerns, we have inves-
tigated the properties of siRNA modified with 20-
deoxy-20-fluoro-b-D-arabinonucleotide units (araF-N
or FANA units). Here we provide evidence that
these modified siRNAs are compatible with the intra-
cellular RNAi machinery and can mediate specific
degradation of target mRNA. We also show that the
incorporation of FANA units into siRNA duplexes
increases activity and substantially enhances
serum stability of the siRNA. A fully modified sense
20-deoxy-20-fluoro-b-D-arabinonucleic acid (FANA)
strand when hybridized to an antisense RNA (i.e.
FANA/RNA hybrid) was shown to be 4-fold more
potent and had longer half-life in serum ( 6h )
compared with an unmodified siRNA (<15 min).
While incorporation of FANA units is well tolerated
throughout the sense strand of the duplex, modifi-
cations can also be included at the 50 or 30 ends
of the antisense strand, in striking contrast to
other commonly used chemical modifications.
Taken together, these results offer preliminary evi-
dence of the therapeutic potential of FANA modified
siRNAs.
INTRODUCTION
Numerous strategies for silencing gene expression with
nucleic acid-based molecules are under development (1,2).
Of these, the hybridization-driven ‘antisense’ strategies, using
ribozymes, DNAzymes and antisense oligonucleotides (AON)
such as chimeric 20-O-alkyl-RNA–DNA (gapmers) or phos-
phorothioate DNA (PS-DNA) have receivedthe greatest atten-
tion and are the subject of numerous reviews [e.g. see Refs.
(2,3)]. More recently, RNA interference (RNAi) has emerged
as an exciting potential alternative to these more classical
approaches (4–10). There are now literally thousands of
reports describing the utility of this method for silencing
genes in living organisms ranging from yeast to mammals
(11–14). The utility of small interfering RNA (siRNA) in vivo
and its possible applications in pharmacotherapy, as with
other oligonucleotide-based therapies, faces some key hurdles
including delivery, cellular uptake and biostability. Initial
work with AONs and siRNAs was undertaken with unmodi-
ﬁed, natural molecules. It soon became clear, however, that
native oligonucleotides were subject to relatively rapid
degradation, primarily through the action of 30 exonucleases,
but not excluding endonuclease attack as well. Oligoribo-
nucleotides (RNA) are, in fact, generally more susceptible
to nuclease degradation than DNA.
AON as well as siRNA molecules are now routinely modi-
ﬁed to enhance their stability, afﬁnity with RNA and biodis-
tributionsince these attributes are requiredif the molecules are
to function as drugs (15–21). In designing new analogues, it is
important to recognize that two key features of siRNA differ
from traditional antisense approaches: (i) duplex RNAs are
recognized and (ii) gene inhibition involves RNA-induced
silencing complex (RISC)—rather than RNase HII—to pro-
mote recognition and cleavage of the mRNA target (5–7,9,10).
Therefore, the most obvious type of modiﬁcation to introduce
into siRNAs is RNA-mimic nucleotides (North or C30-endo
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doi:10.1093/nar/gkl033sugar pucker), that will improve the siRNA properties without
perturbing the A-form helical structure required for activity.
Among this class, a promising modiﬁcation is locked
nucleic acid (LNA), in which the key beneﬁts of improved
thermal stability and biostability, and reduced off target-
effects were achieved with relatively few modiﬁcations that
did not signiﬁcantly compromise siRNA activity (22). With
a few exceptions (23–25), increasing degree of modiﬁca-
tion with RNA-mimic nucleotides, e.g. 20F-RNA, LNA,
boranophosphate-RNA, 20-O-alkyl RNA and phosphoroth-
ioate RNA, impairs activity (25–27). While this may in prin-
ciple be compensated by the nuclease stability and/or
speciﬁcity imparted by certain oligonucleotide chemistries,
the prediction of effective siRNA chemistries remains an
active focus of continued study.
We reported recently on the antisense activity of PS-
FANA–DNA chimeras in cultured cells, and showed that
these compounds maintain high intracellular concentrations
for prolonged periods of time which appears to promote long-
term gene silencing (28). These observations, combined with
the nuclease stability beneﬁt provided by 20-deoxy-20-ﬂuoro-
b-D-arabinonucleic acid (FANA) nucleotides, prompted us to
evaluate whether FANA modiﬁed siRNAs are accepted by
the RISC and regulate gene expression via the RNAi pathway.
Herein we report studies which directly compare the gene
silencing efﬁciency of FANA modiﬁed siRNA and native
siRNA molecules. Our results indicate that the FANA-
containing siRNAs, including FANA:RNA hybrids, trigger
the RNAi pathway and are able to induce sequence-speciﬁc
and selective RNAi to a level surpassing that observed with
native siRNAs. This property, together with the observation
that FANA modiﬁed siRNAs display signiﬁcantly enhanced
nuclease resistance in serum, suggests that these molecules
may ﬁnd utility in therapeutic applications.
MATERIALS AND METHODS
Oligonucleotides
Oligoribonucleotides were obtained commercially from the
University of Calgary DNA Synthesis Laboratory (Calgary,
AB). FANA and FANA modiﬁed siRNAs were prepared
according to the published procedures (29). All oligonu-
cleotides were puriﬁed by anion-exchange high-performance
liquid chromatography followed by desalting (SepPak
cartridges, Millipore, Nepean ON). siRNA duplexes were
obtained by annealing equimolar ratios of the sense and
antisense strands in siRNA suspension buffer (Qiagen,
Mississauga, ON) to a ﬁnal concentration of 20 mM. Duplexes
were heated at 95 C for 5 min and slowly cooled at 4 C O/N.
siRNA duplexes used in this study are listed in Table 1.
Cell culture and transfection
The HeLa X1/5 cell line, expressing the ﬁreﬂy luciferase gene,
was maintained in EMEM supplemented with 10% fetal
bovine serum (FBS), 2 mM L-glutamine, 1% non-essential
amino acids, 1% MEM vitamins, 500 ml/ml G418,
300 mg/ml Hygromycin as described previously (30). For
transfection, 1.0 · 10
5 cells/well in 24-well plates were seeded
the day prior to transfection. The day of transfection, cells
were incubated with 60 nM of siRNA complexed with
Lipofectamine 2000 (Invitrogen, Burlington, ON) in a 1:2
(i.e. 1 mg of siRNA for 2 ml of Lipofectamine 2000) ratio
according to the manufacturer’s recommendations. Dose–
response studies were performed using a ﬁnal concentration
of 60 nM of siRNA whereby the effective siRNA was serially
diluted with a control siRNA thus reducing the effective con-
centration of active oligonucleotide while keeping the ﬁnal
concentration of siRNA constant. Cell viability was deter-
mined by measuring the cell metabolic activity, as an indicator
of cellular toxicity resulting from siRNA transfection, using
the Alamar Blue  ﬂuorimetric assay (Medicorp, Montreal,
QC) as per the manufacturer’s recommendations. This assay
incorporates a ﬂuorometric/colorimetric growth indicator
based on detection of metabolic activity. The luciferase RLU
values will then be normalized to their respective Alamar blue
Table 1. Oligonucleotides and duplexes synthesized in this study
Name Sequence
a EC50 (nM)
siRNA1 50-GCUUGAAGUCUUUAAUUAAgg-30 0.26
30-ggCGAACUUCAGAAAUUAAUU-50
siFANA1 50-GCUUGAAGUCUUUAAUUAATT-30 0.25
30-ggCGAACUUCAGAAAUUAAUU-50
siFANA2 50-GCTTGAAGUCTTUAATTAAtt-30 2.0
30-ggCGAACUUCAGAAAUUAAUU-50
siFANA3 50-GCTTGAAGTCTTTAATTAAGG-30 0.59
30-ggCGAACUUCAGAAAUUAAUU-50
siFANA4 50-GCUUGAAGUCUUUAAUUAAgg-30 0.16
30-gGCGAACUUCAGAAAUUAAUU-50
siFANA5 50-GCUUGAAGUCUUUAAUUAAgg-30 0.52
30-ggCGAACUUCAGAAAUUAAUT-50
siFANA6 50-GCUUGAAGUCUUUAAUUAAgg-30 6.3
30-ggCGAACTTCAGAAATTAATT-50
siFANA7 50-GCUUGAAGUCUUUAAUUAAgg-30 0.06
30-GGCGAACUUCAGAAAUUAAUU-50
siFANA8 50-GCUUGAAGUCUUUAAUUAAgg-30 >10
30-GGCGAACUUCAGAAAUUAAUT-50
siFANA9 50-GCTTGAAGUCTTUAATTAAtt-30 0.11
30-gGCGAACUUCAGAAAUUAAUU-50
siFANA10 50-GCTTGAAGUCTTUAATTAAtt-30 1.7
30-ggCGAACUUCAGAAAUUAAUT-50
siFANA11 50-GCTTGAAGUCTTUAATTAAtt-30 3.6
30-ggCGAACTTCAGAAATTAATT-50
siFANA12 50-GCTTGAAGUCTTUAATTAAtt-30 0.06
30-GGCGAACUUCAGAAAUUAAUU-50
siFANA13 50-GCTTGAAGUCTTUAATTAAtt-30 >10
30-GGCGAACUUCAGAAAUUAAUT-50
siFANA14 50-GCTTGAAGTCTTTAATTAAGG-30 0.24
30-gGCGAACUUCAGAAAUUAAUU-50
siFANA15 50-GCTTGAAGTCTTTAATTAAGG-30 1.5
30-ggCGAACUUCAGAAAUUAAUT-50
siFANA16 50-GCTTGAAGTCTTTAATTAAGG-30 >10
30-ggCGAACTTCAGAAATTAATT-50
siFANA17 50-GCTTGAAGTCTTTAATTAAGG-30 0.17
30-GGCGAACUUCAGAAAUUAAUU-50
siFANA18 50-GCTTGAAGTCTTTAATTAAGG-30 >10
30-GGCGAACUUCAGAAAUUAAUT-50
Control siRNAs
siRNA-CTL 50-AAGCAAUAUUUAAAUCGUAAAgg-30 inactive
30-ggUUCGUUAUAAAUUUAGCAUUU-50
siRNA1-Mi 50-GCUUGAUUCUGAUAAUUAAgg-30 inactive
30-ggCGAACUAAGACUAUUAAUU-50
siFANA17-Mi 50-GCTTGATTCTGATAATTAAGG-30 inactive
30-GGCGAACUAAGACUAUUAAUU-50
aUppercase letters, RNA; lowercase letters, DNA; bold uppercase letters,
FANA; underlined letters, mismatches; siRNA sequences are shown with the
sense strand on top and antisense strand below it.
1670 Nucleic Acids Research, 2006, Vol. 34, No. 6RFU values. Therefore, if any toxicity is induced by the
siRNAs in the tested experimental conditions, it will then
be corrected by this normalization.
Luciferase activity assay
Luciferase activity assays were performed using the luciferase
assay system (BD Bioscience, Mississauga, ON) according to
the manufacturer’s protocol. Brieﬂy, following transfection
with the siRNA, cells were washed with phosphate-buffered
saline (Invitrogen, Burlington, ON) and lysed. Cell lysates
were centrifuged to remove cellular debris and aliquots
were transferred to 96-well lumitrac plates (Ultident; Greiner
Bio-one, Longwood FL). Luminescence was measured using a
microplate luminometer (Luminoskan Ascent, Thermo
LabSystem) immediately following addition of the luciferin
substrate solution. Luminescence values were then normalized
to the cell viability values.
Luciferase mRNA quantification
For real-time PCR analysis, total RNA was extracted using
the RNeasy mini kit (Qiagen, Mississauga, ON) according to
the manufacturer’s protocol and cDNA prepared from 1 mg
total RNA using the SuperScript  II Reverse Transcrip-
tase and random primers (Invitrogen, Burlington, ON).
Quantitative real-time PCR was performed using the SYBR
green reagent and gene-speciﬁc primers for the luciferase
(LUC5013 F1, 50-acgctgggcgttaatcagag-30; LUC5013 R1, 50-
gtcgaagatgttggggtgttg-30; TIB MOLBIOL, Berlin, Germany)
and the housekeeping gene GAPDH (huGAPD forward,
50-ggtggtctcctctgacttc-30; huGAPD reverse, 50-ctcttcctcttgtg-
ctcttg-30; TIB MOLBIOL) according to optimized conditions
and using the LightCycler (Roche, Laval, QC).
Stability of oligonucleotides in serum
siRNAs were diluted in 10% FBS (Wisent, St Bruno, QC) in
DMEM (Invitrogen, Burlington, ON) (1 mgi n5 0ml) and
incubated at 37 C. Aliquots of 5 ml were collected after 0,
0.25, 0.5, 0.75, 1, 2, 6 and 24 h and frozen at  20 Ci n1 0mlo f
1·TBE-loadingbuffer untilanalysed.Samples were separated
on 20% polyacrylamide gel under non-denaturing conditions
and stained with SYBR gold (Invitrogen, Burlington, ON).
Densitometry analysis was performed using the TotalLab soft-
ware and half-life of each siRNA was determined. For stability
studiesinhuman plasma, 2mgofeach siRNA was resuspended
in 10 ml of ice-cold plasma and incubated at 37 C. Aliquots
of 1 ml were collected at the different time points and frozen at
 20 Ci n3 9ml of loading buffer (0.5· TBE, 6% Ficoll).
Samples were separated as described above.
RESULTS
Compatibility of FANA with the cellular
RNAi machinery
To assess the compatibility of FANA with the siRNA machin-
ery, we have evaluated a series of different FANA-containing
siRNA (Table 1 and Figure 1) for their ability to speciﬁcally
inhibit ﬁreﬂy luciferase expression in HeLa X1/5 cells. Cells
were transfected with 60 nM siRNA, and both luciferase
mRNA and luciferase activity were measured 24 h following
transfection and compared with a set of siRNA controls
(Table 1), and results are compiled in Figure 2. Dose–response
studies were also performed and estimated EC50 are presented
in Table 1 while best-ﬁt curves of the most promising siRNAs
are shown in Figure 3. The native siRNA had potency in the
subnanomolar range, consistent with several studies using
similar cell/assay systems [e.g. see (22,25,31)].
Sense and/or antisense strand modifications. We ﬁrst inves-
tigated the effect of introducing FANA units in the sense
strand of the duplex, as this strand has been shown to better
toleratechemicalmodiﬁcations [e.g. (22,25)].Our results indi-
cate that FANA units are well tolerated in the sense strand of
the siRNA as shown by the selective inhibition of luciferase
mRNA and luciferase activity by a series of sense-modiﬁed
siRNA (Table 1 and Figure 2A). Remarkably, an siRNA
having an all-FANA sense strand (siFANA3) showed only
minimal loss of activity when compared with the unmodiﬁed
siRNA (Figure 2A). Activity is ‘rescued’ by introducing
FANA at the 30-terminus of the antisense RNA strand
(dGG-30 !araF-GG-30). In fact, the resulting duplex
siFANA17 (>50% FANA) was more active than the native
siRNA duplex (Table 1 and Figure 3). Interestingly, a duplex
with a fully modiﬁed sense strand (siFANA3, E50  0.6 nM)
was more potent than a duplex with a partially modiﬁed sense
strand (siFANA2, E50 2 nM). None of the siRNA controls,
namely siRNA-CTL, siRNA1-Mi and siFANA17-Mi
(Table 1), had an effect on luciferase activity conﬁrming
the speciﬁcity of the FANA-modiﬁed siRNAs.
We next examined the effect on siRNA activity of
incorporating FANA units at internal and terminal positions
of the antisense strand, which has been reported to be more
sensitive to chemical modiﬁcations compared with sense
strand (22,25). This is most likely due to the importance of
this strand for incorporation into the RISC (50 terminus),
nucleation of binding with target mRNA (positions 2–5 start-
ing from the 50 end) and mRNA cleavage (between positions
10 and 11) (22,26,32,33).
Ourdatashow thatmodiﬁcationsofthe 50 end(siFANA5) or
the 30-dangling dinucleotides (siFANA4 and siFANA7) were
very well tolerated (Table 1 and Figure 2B). For example, the
siRNA with two FANA residues at the 30 end retains activity
and is, in fact, 4-fold more potent than the control (siFANA7;
EC50  0.06 nM). The beneﬁts of 30 end modiﬁcations are
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Figure 1. Chemical structures of FANA and RNA.
Nucleic Acids Research, 2006, Vol. 34, No. 6 1671clearly seen for siFANA12 (EC50  0.06 nM) and siFANA17
(EC50  0.17 nM) which are signiﬁcantly more potent than
the corresponding 30-unmodiﬁed duplexes (siFANA2, EC50
 2.0 nM; siFANA3, EC50  0.59 nM; Table 1). In addition,
no signiﬁcant effect on siRNA potency was observed when
a FANA residue is placed at the 50 end of the antisense
strand (siFANA5; EC50  0.52 nM). When FANA units
were placed at both termini of the antisense strand, a different
picture emerged. For example, a large negative effect on
siRNA potency was observed with siFANA13 (Table 1;
EC50 >10 nM). The same trend was observed for the series
siFANA15, siFANA17 and siFANA18 (Table 1).
Our results also show that FANA substitutions at position
1–2,5–6and13–14 oftheantisensestrand (siFANA6)reduced
siRNA activity suggesting that (i) these positions may play a
critical role forthe siRNA function (Figure2B), and/or(ii) that
some property of the FANA T nucleoside is responsible for the
observed lowered activity. Interestingly, this loss of activity is
compensated by introducing six other FANA units at juxta-
posed positions within the sense strand, providing a duplex
that now has excellent activity (siFANA11, EC50 3.6 nM).
This shows that the effects observed depend on not only
the number of modiﬁcations but also the precise location
and arrangement of the FANA sugar with the siRNA duplex.
Persistence of activity of FANA-containing siRNA
To further characterize the inhibitory properties of the FANA
siRNAs in our cells stably expressing the luciferase mRNA
target, we carried out a time-course experiment, observing
luciferase expression on 4, 8, 24, 48, 72 and 96 h after trans-
fection (Figure 4). Luciferase suppression lasted over the 4day
period, consistent with previous observations (31,34). Our
resultsalsoindicate thatthehigherpotencyofFANA-modiﬁed
siRNA over native siRNA was also maintained over this
time period. For example, at the 96 h time point, siFANA7,
siFANA3 and siFANA 17 were more potent than the unmodi-
ﬁed siRNA duplex (Figure 4). The data given below suggest
that increased nuclease stability of FANA modiﬁed siRNAs
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Figure2.EfficacyofthedifferentsiRNAsatinhibitingluciferaseinHeLaX1/5
cells. Cells were transfected with 60 nM siRNA with modifications in the
sense strand only (A), in the antisense strand only (B) or in both sense and
antisense strands (C). Luciferase activity levels were measured 24 h post-
transfection and normalized to metabolic activity. The normalized luciferase
activitywasthendeterminedasa percentage ofluciferaseactivityascompared
with an unrelevant control siRNA (siRNA-CTL) set at 100%. Data represent
mean normalized luciferase activity ± SEM. Luciferase mRNA levels were
quantified by real-time PCR analysis (relative to expression of the house keep-
inggeneGAPDH)24hpost-transfection.BarsshowmeanLuciferase/GAPDH
ratios ± SEM.
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Figure 3. Potency of FANA-containing siRNA at inhibiting the luciferase
activity. Dose-responses were obtained for each siRNA by transfecting cells
with different amounts of active siRNA for 24 h. Luciferase activity was mea-
sured and values normalized to the metabolic activity and compared with a
control siRNA (siRNA-CTL) set at 100%. Data represent mean normalized
luciferase activity ± SEM.
1672 Nucleic Acids Research, 2006, Vol. 34, No. 6may be responsible, at least in part, for the persistent and
potent activity of FANA-containing siRNAs.
Serum stability
FANA AONs are more resistant to endo and exonucleases, and
this resistance is further enhanced if the FANA-modiﬁed
nucleosides are connected by phosphorothioate linkages.
PS-FANA AONs, for example, are >20-fold more stable
than PS-DNA towards 30-exonuclease hydrolysis [(30) and
M. J. Damha and K.-L. Min, unpublished data). To investigate
whether phosphodiester (PO)-linked FANA would provide
similar enhancement of nuclease resistance to siRNA
duplexes, we assessed the stability of unmodiﬁed and modiﬁed
siRNA in fetal bovine (Figure 5) and human plasma (data not
shown). As expected, the unmodiﬁed siRNA was rapidly
degraded within 15 min (Figure 5A). A similar degradation
proﬁle was observed with siFANA7 (two araF-G residues at
the 30 end of the antisense strand) whereas siFANA3 with a
fully modiﬁed sense strand has a half-life of  5 h (Figure 5B).
When siFANA3 is further modiﬁed to give siFANA17, the
serum half-life increases to  6 h (Figure 5B). Comparable
stability proﬁleswhereobservedwhenthe same duplexes were
exposed to human plasma (data not shown).
DISCUSSION
A growing number of oligonucleotide-based approaches
exist for the regulation of gene expression in mammalian
cells (2,3). Selective gene knockdown is now widely used
for target validation and therapeutic purposes. The recent
discovery of RNAi (4,5) has renewed interest in antisense-
based approaches (AON, siRNA). However, their use for
in vivo applications faces key limitations relating to delivery,
cellular uptake and biostability.
We have demonstrated previously that incorporation of
FANA residues into PS-DNA AONs leads to signiﬁcant
improvement in terms of potency and stability of the AON
(28,30). We have also shown that PS-FANA–DNA chimeras
trigger RNase H-mediated mRNA degradation more efﬁ-
ciently than PS-DNA or PS-20OMe-RNA–DNA chimeras of
equal designs, in part because the arabinose sugar does not
alter the overall helical structure of the corresponding AON/
mRNA hybrid when compared with the native DNA/RNA
substrate (35,36). Given that FANA is globally similar in
structure to DNA, substitutions of RNA with FANA units
is expected to result in structural perturbation of RNA
duplexes, and hence inﬂuence the ability of siRNA duplexes
to serve as substrates for RISC enzymes involved in the RNAi
pathway. Remarkably, here we ﬁnd that FANA is particularly
well suited for the RNAi machinery whilst imparting improve-
ments key to the development of siRNA as prospective drugs.
Based on the data obtained (Table 1), FANA is one of the very
few modiﬁcations (24,25) that can drastically enhance serum
stability oftheduplex(Figure5)whileincreasingpotencyover
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Figure 4. Duration of activity of modified siRNA. Cells were transfected with
60 nM siRNA. Luciferase activity was measured 4, 8, 24, 48, 72 and 96 h
post-transfection. Data represent mean normalized luciferase activity ± SEM
compared with a control siRNA (siRNA-CTL) set at 100%.
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Figure 5. Serum stability of FANA-containing siRNA. The different siRNAs
were incubated in 10% FBS at 37 C and aliquots were taken at the time points
indicated.(A) The siRNA were separated by PAGE and visualized with SYBR
gold. ‘ds’ depicts double-stranded siRNA marker and ‘ss’ single-stranded.
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Nucleic Acids Research, 2006, Vol. 34, No. 6 1673native siRNA (up to 4-fold). For example, our data indicate
that the modest substitution of two ribose with arabinose
(FANA) at the 30 end of the antisense strand (siFANA7),
was sufﬁcient to increase the potency over the native siRNAs,
with gene silencing observed to persist over a 4 day period.
Moreover, we showed that an all-FANA:RNA hybrids (e.g.
siFANA3, siFANA14) enter the RNAi pathway, and that their
activity could also be increased beyond that of the native
siRNA (siFANA17) by introducing further modiﬁcations at
the 30 end of the antisense strand. Since the plasma stability of
siFANA7 was comparable with that of native siRNA, we
suggest that the increased potency of siFANA7 (compared
withnative siRNA) and siFANA17(compared with siFANA3)
is due to a change in relative thermal stabilities of the
duplex termini and/or an improved recognition of the
FANA 30-overhang by the Argonaute PAZ domain. Indeed,
O’Toole et al. (32) have shown that the nature and base stack-
ing of a 30 double nucleotide overhang can make a signiﬁcant
contribution to the thermodynamic stability of RNA duplexes.
As RISC incorporates the siRNA strand whose 50 end is
least stable, this would explain an increase in RISC loading
efﬁcacy for siFANA7 (compared with unmodiﬁed siRNA and
siFANA5) and thus, increased activity (37,38). Furthermore,
recent crystallographic studies by Lingel et al. (39) showed
that the Argonaute PAZ domain forces the 30 overhanging
nucleotides to adopt a DNA-like (South/East) sugar pucker
and an anti base orientation, both of which are favoured and
maintained by FANA nucleotides (35,36). Given the con-
formational bias of the 20-deoxy-20-ﬂuoro-arabinose sugars
(35,36), the entropic penalty for PAZ recognition of an
FANA overhang is expected to be reduced relative to the
more ﬂexible DNA or the C30-endo RNA overhangs. This
would favour FANA over DNA or RNA as the dangling
nucleotides in siRNAs.
In conclusion, FANA substitutions, particularly when made
in the sense strand together with modiﬁcation of the 30-over-
hanging end of the antisense strand, can lead to increased
activityofthe siRNA. Inaddition FANA substitutionenhances
the resistance of the siRNA duplex to degradation in serum-
containing medium, a property that may impact the future
therapeutic development of chemically modiﬁed siRNAs.
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